EFFECTS OF ARGENTINA HYPERINFLATIONARY ACCOUNTING ON Q4 AND FULL YEAR 2023 RESULTS

“In a nutshell, due to the abrupt devaluation of the Argentine peso in late December, accounting rules required us to record a non-cash negative impact on our 4Q23 and full year 2023 earnings. But excluding this extraordinary accounting effect, our core business is solid with good prospects. We present this information proactively and transparently so investors understand this is an isolated event, not indicative of operating issues. We remain committed to delivering value for our shareholders with a strong and growing business.”

MEXICO CITY, Feb. 15, 2024 /PRNewswire/ — Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, provides a preliminary overview of 2023 full year performance relative to hyperinflationary accounting for its Argentina subsidiary.

The significant devaluation of the Argentine peso on December 13, 2023 resulted in an extraordinary non-cash accounting impact on Genomma Lab’s 2023 fourth quarter and financial year results, also adversely affecting the Company’s 2023 net income. Genomma provides relevant preliminary financial results for the fourth quarter and full year ended December 31, 2023 on its investor relations site.

For a full version of this press release, please visit: https://inversionistas.genommalab.com/wp-content/uploads/2024/02/Argentina-Hyperinflation-Q4_2023_FINAL.pdf

About Genomma Lab Internacional 

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of Premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low‐cost, highly flexible supply chain operating model.

For more information visit: www.genommalab.com Genomma Lab’s shares are listed on the Mexican Stock Exchange under the ticker “LABB” (Bloomberg: LABB:MM).

Note on Forward-Looking Statements
This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like “believe,” “anticipate,” “expect,” “envisages,” “will likely result,” or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products attained by competitors; challenges inherent in new product development; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws; changes in behavior and spending patterns of purchasers of products and services; financial instability of international economies and legal systems and sovereign risk. A further list and descriptions of these risks, uncertainties and other factors can be found within the Company’s related filings with the Bolsa Mexicana de Valores. Any forward-looking statement made in this release speaks only as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View original content:https://www.prnewswire.com/news-releases/effects-of-argentina-hyperinflationary-accounting-on-q4-and-full-year-2023-results-302063608.html

SOURCE Genomma Lab Internacional, S.A.B. de C.V.